Table 6: Relationship between demographic and clinical characteristics and the presence of residual BNM (BNMr) in evaluated cancer patients.
|
Characteristics |
|
Residual BNM |
P* |
|||
|
Yes (n = 5) |
% |
No (n = 114) |
% |
n (n = 119) |
||
|
Gender |
|
|
|
|
|
|
|
Female |
4 |
80.0 |
88 |
77.2 |
92 |
0.682 |
|
Male |
1 |
20.0 |
26 |
22.8 |
27 |
|
|
Age Range |
|
|
|
|
|
|
|
24 to 34 |
0 |
0.0 |
11 |
9.6 |
11 |
0.353 |
|
35 to 45 |
0 |
0.0 |
27 |
23.7 |
27 |
|
|
46 to 56 |
3 |
60.0 |
33 |
28.9 |
36 |
|
|
57 to 67 |
2 |
40.0 |
25 |
21.9 |
27 |
|
|
68 and above |
0 |
0.0 |
18 |
15.8 |
18 |
|
|
PA Classification |
|
|
|
|
|
|
|
Normal |
3 |
60.0 |
50 |
43.9 |
53 |
0.167 |
|
Borderline |
2 |
40.0 |
20 |
17.5 |
22 |
|
|
High |
0 |
0.0 |
44 |
38.6 |
44 |
|
|
Surgery Time |
|
|
|
|
|
|
|
< 1h |
2 |
40.0 |
8 |
7.0 |
10 |
0.008* |
|
1h to 2h |
3 |
60.0 |
44 |
38.6 |
47 |
|
|
> 2h |
0 |
0.0 |
62 |
54.4 |
62 |
|
|
BNM Dose |
|
|
|
|
|
|
|
30 to 50 mg |
5 |
100.0 |
86 |
75.4 |
91 |
0.693 |
|
60 to 80 mg |
0 |
0.0 |
21 |
18.4 |
21 |
|
|
> 80 mg |
0 |
0.0 |
7 |
6.1 |
7 |
|
|
*Significant value for p < 0.05 (5%) |
||||||
|
Pearson's Chi-square test |
||||||